Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy ( OX‐IRIS ) as Chemotherapy for Unresectable Pancreatic Cancer ( HGCSG 1403)

(2021) Yasuyuki Kawamoto et al.   ONCOLOGIST

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

(2019) Takahiro Akahori et al.   ONCOLOGIST

A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer

(2018) Masato Ozaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer

(2018) Takuya Ishikawa et al.   ONCOLOGY

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

(2016) Stacey M Stein et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

(2016) Hideki Ueno et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma

(2015) Hiroaki Yanagimoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

(2014) Takuji Okusaka et al.   CANCER SCIENCE

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

(2013) Hideki Ueno et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE